The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK

The Journal of clinical endocrinology and metabolism20 Dec 2013Cited by 9 (Europe PMC)

PMID24178787PMCIDPMC3879673DOI10.1210/jc.2013-3436PepBankPUB-24178787

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese adults with reduced GH secretion, tesamorelin raised IGF-I more than placebo after 12 months.
In plain wordsIn obese adults with low growth hormone, tesamorelin raised IGF-I more than placebo after 12 months.
Peptide
Tesamorelin
Outcome
IncreaseIGF-I change at 12 months
Study
n = 39
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
IGF-I change
102.9 ug/L
tesamorelin
IGF-I change
22.8 ug/L
placebo
Source sentences
Summary
After 12 months, tesamorelin treatment led to a significantly greater increase in IGF-I than did placebo treatment (change, 102.9±31.8 μg/L vs 22.8±8.9 μg/L, tesamorelin vs placebo; P=.02).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 39 obese men and women with reduced GH secretion as determined by GHRH-arginine stimulation tests underwent magnetic resonance spectroscopy as part of a 12-month, double-blind, randomized, placebo-controlled trial comparing tesamorelin vs placebo.
Report a problemFND-2417878701
02HumanRandomized controlled trialMechanism
In obese adults with reduced GH secretion, larger increases in IGF-I were positively associated with improved phosphocreatine recovery.
In plain wordsIn obese adults with low growth hormone, bigger IGF-I increases were linked to better phosphocreatine recovery.
Peptide
Tesamorelin
Outcome
Not applicableAssociation of IGF-I increase with PCr recovery (ViPCr)
Study
n = 39
Outcome group
Mitochondrial function · Endocrine and hormones
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Correlation R (IGF-I vs ViPCr)
0.56
all subjects
Source sentences
Summary
We demonstrated a significant positive relationship between increases in IGF-I and improvements in PCr recovery represented as ViPCr (R=0.56; P=.01).
2 context sentences(design, population, supporting numbers)
Summary · context
PCr recovery after submaximal exercise was assessed at baseline and at 12 months.
Summary · context
A total of 39 obese men and women with reduced GH secretion as determined by GHRH-arginine stimulation tests underwent magnetic resonance spectroscopy as part of a 12-month, double-blind, randomized, placebo-controlled trial comparing tesamorelin vs placebo.
Report a problemFND-2417878702
03HumanRandomized controlled trialMechanism
In obese adults with reduced GH secretion, the association between IGF-I and phosphocreatine recovery stayed significant after adjusting for age, sex, race, ethnicity, body composition and insulin sensitivity.
In plain wordsIn obese adults with low growth hormone, the IGF-I link to phosphocreatine recovery held after adjusting for age, sex, race, body composition and insulin sensitivity.
Peptide
Tesamorelin
Outcome
Not applicableAssociation of IGF-I with PCr recovery after adjustment
Study
n = 39
Outcome group
Mitochondrial function · Endocrine and hormones
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
This association remained significant after controlling for age, sex, race, ethnicity, and parameters of body composition and insulin sensitivity (all P<.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 39 obese men and women with reduced GH secretion as determined by GHRH-arginine stimulation tests underwent magnetic resonance spectroscopy as part of a 12-month, double-blind, randomized, placebo-controlled trial comparing tesamorelin vs placebo.
Report a problemFND-2417878704
04HumanRandomized controlled trialMechanism
Among obese adults with reduced GH secretion treated with tesamorelin, the positive association between IGF-I and phosphocreatine recovery was stronger.
In plain wordsAmong obese adults with low growth hormone given tesamorelin, IGF-I rises were more strongly linked to better phosphocreatine recovery.
Peptide
Tesamorelin
Outcome
Not applicableAssociation of IGF-I increase with PCr recovery, tesamorelin group only
Study
n: not reported in source
Outcome group
Mitochondrial function · Endocrine and hormones
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Correlation R (IGF-I vs ViPCr)
0.71
tesamorelin only
Source sentences
Summary
The association between IGF-I and PCr recovery was even stronger among subjects treated with tesamorelin only (ViPCr: R=0.71; P=.03).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 39 obese men and women with reduced GH secretion as determined by GHRH-arginine stimulation tests underwent magnetic resonance spectroscopy as part of a 12-month, double-blind, randomized, placebo-controlled trial comparing tesamorelin vs placebo.
Report a problemFND-2417878703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00675506

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

Massachusetts General Hospitaln = 60Jul 2008 to Jan 2012

Abdominal Obesity · Growth Hormone Deficiency

Trial page ClinicalTrials.govUpdated 13 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.